Galapagos NV

Thank you, Operator, and welcome all to the audio webcast of Galapagos' H1 2023 results. I'm Sophie van Heestel, Investor Relations, representing the reporting team at Galapagos. This recorded webcast is accessible via the Galapagos website homepage and will be available for download and replay later on today. I would like to remind everyone that we will be making forward-looking statements during today's webcast. These forward-looking statements include remarks concerning future developments of the pipeline and our company and possible changes in the industry and competitive environments. Because these forward-looking statements involve risks and uncertainties, Galapagos' actual results may differ materially from the results expressed or implied in these statements. Today's speakers will be Paul Stoffels, CEO, and Ted Huston, CFO and COO. Paul will reflect on the operational highlights and provide an update on our pipeline. Ted will go over the commercial and financial results. You will see a presentation on screen. We estimate that the prepared remarks will take about 25 minutes. Then we'll open it up to Q&A with Paul and Ted, joined by Michele Manto, Chief Commercial Officer, and Daniele D'Ambrosio, Head of Immunology. And with that, I'll now turn over to Paul.

Thank you, Sophie, and thank you all for joining today's webcast. I'm very pleased to introduce to you Tad Houston. Tad joined Galapagos as our new CFO, COO, as of July 1. Over the years, Tad gained experience through several positions in finance, commercial, BD, and operations. He joined us from Kite Pharma, where he was Senior VP Finance and Corporate Operations. And before he was CFO of Livanova, a listed medtech company. That was the CFO of J&J Medical Devices and CFO of Janssen R&D in earlier years. That spent four years in China as the president of Janssen China for Janssen. Ted and I have known each other for quite some time. I worked together with Ted at J&J where he held a number of leadership positions for more than 25 years. And he was instrumental in transformational phase of Janssen Global R&D. It goes without saying that his knowledge of R&D and cell therapy is a perfect fit for our company. We are very excited to have Tad on the board. On today's call, Tad will present the operational and financial section.

Tad, thanks for the introduction, Paul, and it's great to be here. I'm so excited to be joining forces with you again, Paul, and to work together. with the Galapagos team to create value for our stakeholders.